JP6389163B2 - フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法 - Google Patents

フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法 Download PDF

Info

Publication number
JP6389163B2
JP6389163B2 JP2015505951A JP2015505951A JP6389163B2 JP 6389163 B2 JP6389163 B2 JP 6389163B2 JP 2015505951 A JP2015505951 A JP 2015505951A JP 2015505951 A JP2015505951 A JP 2015505951A JP 6389163 B2 JP6389163 B2 JP 6389163B2
Authority
JP
Japan
Prior art keywords
acid sequence
seq
nucleic acid
envelope glycoprotein
consensus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015505951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527297A (ja
Inventor
ビー ウェイナー デイビッド
ビー ウェイナー デイビッド
シェドロック デボン
シェドロック デボン
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2015527297A publication Critical patent/JP2015527297A/ja
Application granted granted Critical
Publication of JP6389163B2 publication Critical patent/JP6389163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015505951A 2012-04-12 2013-04-12 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法 Active JP6389163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623428P 2012-04-12 2012-04-12
US61/623,428 2012-04-12
PCT/US2013/036413 WO2013155441A1 (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153310A Division JP7164353B2 (ja) 2012-04-12 2018-08-16 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法

Publications (2)

Publication Number Publication Date
JP2015527297A JP2015527297A (ja) 2015-09-17
JP6389163B2 true JP6389163B2 (ja) 2018-09-12

Family

ID=49328209

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015505951A Active JP6389163B2 (ja) 2012-04-12 2013-04-12 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2018153310A Active JP7164353B2 (ja) 2012-04-12 2018-08-16 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2020153758A Pending JP2021001191A (ja) 2012-04-12 2020-09-14 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2022039450A Pending JP2022078289A (ja) 2012-04-12 2022-03-14 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2024187660A Pending JP2025020200A (ja) 2012-04-12 2024-10-24 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018153310A Active JP7164353B2 (ja) 2012-04-12 2018-08-16 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2020153758A Pending JP2021001191A (ja) 2012-04-12 2020-09-14 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2022039450A Pending JP2022078289A (ja) 2012-04-12 2022-03-14 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2024187660A Pending JP2025020200A (ja) 2012-04-12 2024-10-24 フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法

Country Status (9)

Country Link
US (5) US9597388B2 (enExample)
EP (2) EP4190350A1 (enExample)
JP (5) JP6389163B2 (enExample)
KR (5) KR20220012403A (enExample)
CN (2) CN104884083A (enExample)
AU (1) AU2013245729B2 (enExample)
CA (2) CA3194125A1 (enExample)
IN (1) IN2014DN09351A (enExample)
WO (1) WO2013155441A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019006787A (ja) * 2012-04-12 2019-01-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939572A1 (en) * 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
EP2944321A1 (en) * 2014-05-12 2015-11-18 Institut De Recherche Pour Le Développement (IRD) Immunogenic peptides of EBOLA and applications thereof
ES2777323T3 (es) 2014-09-03 2020-08-04 Bavarian Nordic As Procedimientos y composiciones para inducir inmunidad protectora contra infección por filovirus
EP3188754A1 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
SG10201901735XA (en) 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
KR102586707B1 (ko) * 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
WO2016079572A1 (en) * 2014-11-21 2016-05-26 Wayengara Misaki Conserved b cell epitopes of filovirus glycoprotein and their use as either biomarkers or therapeutics and sub-unit vaccines for ebola virus and marburg virus
US20170326225A1 (en) * 2014-12-16 2017-11-16 Curevac Ag Ebolavirus and marburgvirus vaccines
MX2017009698A (es) * 2015-01-28 2018-01-18 Integrated Biotherapeutics Inc Composiciones de inmunoglobulina equina y usos para tratar enfermedades mediadas por filovirus.
CN105582532A (zh) * 2015-08-30 2016-05-18 李小彦 可溶性埃博拉病毒包膜蛋白疫苗的制备方法及其用途
SG11201809780WA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
WO2017211843A1 (en) * 2016-06-07 2017-12-14 Abivax Antiviral polyclonal antibodies against ebola virus and the uses thereof
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US11186626B2 (en) * 2016-10-11 2021-11-30 Integrated Biotherapeutics, Inc. Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
EA201892124A1 (ru) 2016-12-02 2019-04-30 Дэвид Б. Уэйнер Днк-конструкции антител и способы их применения
WO2018183435A1 (en) * 2017-03-28 2018-10-04 Children's Hospital Medical Center Vlp-based bivalent ebola vaccines and methods of making and using same
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
NL268156A (enExample) 1960-08-22
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DK0681483T3 (da) 1993-01-26 2005-11-21 Univ Pennsylvania Præparater og fremgangsmåder til administration af genetisk materiale
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
CN1198665C (zh) 1997-04-03 2005-04-27 依莱克脱罗弗克脱联合股份有限公司 将药物和核酸导入骨骼肌的方法
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
EP1086239A1 (en) 1998-06-08 2001-03-28 Valentis Inc. Formulations for electroporation
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
WO2002079239A2 (en) * 2001-01-31 2002-10-10 U.S. Army Medical Research Institute Of Infectious Diseases Chimeric filovirus glycoprotein
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
WO2003028632A2 (en) * 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
WO2003092582A2 (en) * 2002-04-30 2003-11-13 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
EP2364769B1 (en) 2003-05-30 2016-01-13 VGXI, Inc. Devices and methods for biomaterial production
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
JP5046941B2 (ja) * 2004-09-27 2012-10-10 アメリカ合衆国 エボラ及び他のウイルスに対する防御に最適化されたワクチン
CA2636111C (en) * 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
US8796013B2 (en) 2007-12-18 2014-08-05 Trustees Of Boston University Pre-or post-exposure treatment for filovirus or arenavirus infection
US10071154B2 (en) * 2008-04-04 2018-09-11 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
JP5963442B2 (ja) * 2008-05-28 2016-08-03 ブイジーエックス ファーマシューティカルズ， エルエルシー 免疫応答を誘発する天然痘ｄｎａワクチンおよびその中の抗原
WO2010057159A2 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
MX2011005171A (es) * 2008-11-21 2011-05-30 Bavarian Nordic As Vector que comprende multiples secuencias de nucleotidos homologas.
EP2473525A4 (en) * 2009-09-02 2013-08-21 Us Army MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS
WO2012020077A1 (en) 2010-08-11 2012-02-16 Inserm (Institut Mational De La Santé Et De La Recherche Médicale) Methods of growing an embryo to a blastocyst stage of development
EP2632484B1 (en) 2010-10-28 2018-02-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Filovirus fusion proteins and their uses
CA2826594C (en) 2011-02-03 2019-09-17 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
CA3194125A1 (en) * 2012-04-12 2013-10-17 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019006787A (ja) * 2012-04-12 2019-01-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP7164353B2 (ja) 2012-04-12 2022-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法

Also Published As

Publication number Publication date
KR20240010758A (ko) 2024-01-24
US20170165350A1 (en) 2017-06-15
JP2025020200A (ja) 2025-02-12
JP7164353B2 (ja) 2022-11-01
CA3194125A1 (en) 2013-10-17
KR102877352B1 (ko) 2025-10-29
US20240100143A1 (en) 2024-03-28
EP2836230A1 (en) 2015-02-18
CA2870293A1 (en) 2013-10-17
US10034930B2 (en) 2018-07-31
CA2870293C (en) 2023-05-09
IN2014DN09351A (enExample) 2015-07-17
EP2836230B1 (en) 2022-09-07
CN104884083A (zh) 2015-09-02
EP4190350A1 (en) 2023-06-07
US20180344840A1 (en) 2018-12-06
KR20140146652A (ko) 2014-12-26
KR102351881B1 (ko) 2022-01-18
AU2013245729A1 (en) 2014-10-30
KR102146904B1 (ko) 2020-08-24
CN110051835A (zh) 2019-07-26
JP2021001191A (ja) 2021-01-07
US20150335726A1 (en) 2015-11-26
JP2015527297A (ja) 2015-09-17
WO2013155441A1 (en) 2013-10-17
US11723969B2 (en) 2023-08-15
KR20250156204A (ko) 2025-10-31
US10765733B2 (en) 2020-09-08
US20200390880A1 (en) 2020-12-17
JP2022078289A (ja) 2022-05-24
JP2019006787A (ja) 2019-01-17
EP2836230A4 (en) 2016-03-02
AU2013245729B2 (en) 2016-09-29
KR20200104917A (ko) 2020-09-04
KR20220012403A (ko) 2022-02-03
US9597388B2 (en) 2017-03-21

Similar Documents

Publication Publication Date Title
JP6389163B2 (ja) フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP7584770B2 (ja) フィロウイルスコンセンサス抗原、核酸構築物及びそれを用いたワクチン、ならびにその使用方法
EA045714B1 (ru) Консенсусные антигены филовируса, конструкции нуклеиновых кислот и вакцины, полученные на их основе, и способы их применения

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389163

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250